Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in
combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration
and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an
extension treatment for up to 52 weeks.